Published on Jan-08-2013 10:41 PM :
About the Eeva™ Test
IVF patients outside of the U.S. now have access to a new, non-invasive technology created to help embryologists track the health and development of embryos from the moment of fertilization. The product, called Eeva (Early Embryo Viability Assessment) takes photos of the developing embryos every five minutes; the time-lapse images are analyzed by the system's software which is said to help embryologists identify anomalies sooner.
If it lives up to the preliminary research, Eeva could improve IVF outcomes, increasing pregnancy and live birth rates while decreasing the number of embryos needed to transfer.
Eeva Designed to Improve IVF Outcomes by Assessing Embryo Viability with a New Level of Accuracy –
The Eeva Test, developed, is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. Eeva uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It predicts with high accuracy at the cleavage stage (day 3) which embryos will likely grow to the blastocyst stage (day 5-6), a critical milestone in embryo development.
Eeva is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select embryo(s) for transfer. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters, not only providing novel quantitative information, but also ensuring consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimise the treatment path for their patients undergoing IVF procedures.
The safety and efficacy of Eeva were validated in a prospective, multi-centre, 160-patient clinical trial, results of which were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey. In the study, Eeva was able to predict blastocyst formation at the cleavage stage with 85 percent specificity, reducing the false positive rate from 43 percent to 15 percent compared with traditional morphology selection. Eeva also demonstrated the ability to track and analyse cell division timings with greater than 90 percent accuracy. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists.